1. US Centers for Disease Control and Prevention. Active Bacterial Core surveillance report, Emerging Infections Program Network, Streptococcus pneumoniae, 2010. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at http://www.cdc.gov/abcs/reports-findings/survreports/spneu10-orig.html. Accessed October 1, 2019.
2. US Centers for Disease Control and Prevention. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012; 61(40):816–19.
3. An intervention to improve pneumococcal vaccination uptake in high risk 50–64 years old vs. expanded age-based recommendations: An exploratory cost-effectiveness analysis;Wateska;Hum Vacc Immunother,2019
4. Clinical and economic burden of pneumococcal disease in US adults aged 19–64 years with chronic or immunocompromising diseases: and observational database study;Zhang;BMC Infect Dis,2018
5. US Centers for Disease Control and Prevention. Vaccination Coverage Among Adults in the United States. National Health Interview Survey. 2016. Available at: https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2016.html. Accessed October 31, 2019.